Abstract
Cardiovascular complications are the most common causes of morbidity and mortality in diabetic patients. Coronary atherosclerosis is enhanced in diabetics, whereas myocardial infarction represents 20% of deaths of diabetic subjects. Furthermore, re-infarction and heart failure are more common in the diabetics. Diabetic cardiomyopathy is characterized by an early diastolic dysfunction and a later systolic one, with intracellular retention of calcium and sodium and loss of potassium. In addition, diabetes mellitus accelerates the development of left ventricular hypertrophy in hypertensive patients and increases cardiovascular mortality and morbidity. Treating the cardiovascular problems in diabetics must be undertaken with caution. Special consideration must be given with respect to the ionic and metabolic changes associated with diabetes. For example, although ACE inhibitors and calcium channel blockers are suitable agents, potassium channel openers cause myocardial preconditioning and decrease the infarct size in animal models, but they inhibit the insulin release after glucose administration in healthy subjects. Furthermore, potassium channel blockers abolish myocardial preconditioning and increase infarct size in animal models, but they protect the heart from the fatal arrhytmias induced by ischemia and reperfusion which may be important in diabetes. For example, diabetic peripheral neuropathy usually presents with silent ischemia and infarction. Mechanistically, parasympathetic cardiac nerve dysfunction, expressed as increased resting heart rate and decreased respiratory variation in heart rate, is more frequent than the sympathetic cardiac nerve dysfunction expressed as a decrease in the heart rate rise during standing.
Similar content being viewed by others
References
Manual-Malacara J, Eugenia Davalos L, Cervantes F, Castillo J, Velasco E: Risk factors of the complications of diabetes mellitus. J Rev Invest Clin 43: 3–9, 1991
Krankenhaus, Munchen-Schwabing: Epidemiology and risk factors of macrovascular disease in diabetes mellitus. J Horm Metab Res Suppl 22: 8–11, 1990
Knowles HD Jr: Long term juvenile diabetes treated with un-measured diet. J Trans Assoc Am Physicians 84: 95, 1971
Partamian JO, Bradley RF: Acute myocardial infarction in 258 cases of diabetes: Immediate mortality and five year survival. N Engl J Med 273: 455, 1965
Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD: Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 91: 635–640, 1995
Lehto S, Pyorala K, Miettinen H, Ronnemaa T, Palomaki P, Tuomilehto J, Lakso M: Myocardial infarct size and mortality in patients with non-insulin dependent diabetes mellitus. J Intern Med 236: 291–297, 1994
Tosaki A, Engelman DT, Engekman RM, Das DK: Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. J Pharm Exp Ther 275: 1115–1123, 1995
Khandoudi N, Bernard M, Cozzen P, Fenvary D: Mechanism of intracellular pH regulation during postischemic reperfusion of diabetic rat hearts. J Diabetes 44: 196–202, 1995
Carl FV Jr, Roberts WC: The extramural and intramural coronary arteries in juvenile diabetes mellitus: Analysis of nine necropsy patients aged 19 to 38 years with the onset of diabetes before age 15 years. Amer J Med 64: 221, 1978
Salomon NW, Page US, Okies JE, Stephens J, Krause AH, Bigelow JC: Diabetes mellitus and coronary artery bypass: Short term risk and long term prognosis. J Thor Cardiovasc Surg 85: 264, 1983
Weishaar RE, Simpson RU: Vitamin D3 and cardiovascular function in rats. J Clin Invest 79: 1706, 1987
Catham J C, Forder JR: A 13C-NMR study of glucose oxidation in the intact functioning rat heart following diabetes-induced cardiomyopathy. J Mol Cell Cardiol 25: 1203–1213, 1993
Broderick TL, Quinney HA, Lopaschuk GD: L-carnitine increases glucose metabolism and mechanical function following ischemia in diabetic rat heart. J Cardiovasc Res 29: 373–378, 1995
Higochi M, Miyagi K, Nakasone J, Sakunashi M: Role of high glycogen in underperfused diabetic rat hearts with added norepinephrine. J Cardiovasc Pharmacol 26: 899–907, 1995
Fein F: Diabetic cardiomyopathy. J Diabetes Care 13: 1169–1179, 1990
Shinmura K, Tani M, Suganuma Y. Hasegawa H, Kawamura M, Nakamura Y, Hashimoto J, Kubo A: 123I-beta-methyl-iodophenylpentadecanoic acid myocardial scintigraphy in diabetic patients without overt ischemic heart disease. J Cardiol 26: 23–32, 1995
Dai S, Mc Neill JH: Ascorbic acid supplementation prevents hyperlipidemia andimproves myocardial performance in streptozotocin diabetic rats. J Diab Res Clin Pract 27: 11–18, 1995
Dai S, Fraser H, Yuen VG, Mc Neill JH: Improvement in cardiac function in streptozotocin-diabetic rats by salt loading. Can J Physiol Pharmacol 72: 1288–1293, 1994
Valensi P: Pathological role of hyperinsulin in macroangiopathy. J Press Med 21: 1307–1311, 1992
Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmed MR, Haider B: Evidence of cardiomyopathy in familial diabetes mellitus. J Clin Invest 60: 885, 1997
Fein FS, Capasso JM, Aronson RS, Cho S, Nordin C, Miller GB, Sonnenblick EH, Factor SM: Combined renovascular hypertension and diabetes in rats: a new preparation of congestive cardiomyopathy. Circulation 70: 318, 1984
Uusittupa M, Siitonen O, Aro A, Korhonen T, Pyorala K: Effect of correlation of hyperglycemia on left ventricular function in non-insulin dependent diabetics. Acta Med Scand 23: 213–363, 1983
Raev DC: Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? J Diabetes Care 17: 633–639, 1994
Uusitupa MI, Mustonen JN, Airaksinen KE: Diabetic heart muscle disease. J Ann Med 22: 377–386, 1990
Penpargkul S, Fein F, Sonnenblick EH, Scheuer J: Depressed cardiac sarcoplasmic reticulum function in diabetic rats. J Mol Cell Cardiol 13: 303, 1981
Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T: Left ventricular mass in diabetes-hypertension. J Arch Intern Med 152: 1001–1004, 1992
Rosen P, Pogasta G, Tschope D, Addicks K, Reinauer H: Diabetic cardiomyopathy. Pathophysiological concepts and therapeutic approaches J Klin Wochen 69: 3–15, 1992
Lawton JS, Sepic JD, Allen CT, Hsia PW, Domiano RJ: Myocardial protection with potassium channel openers is as effective as St Thomas' solution in the rabbit heart. J Ann Thorac Surg 62: 31–39, 1996
Links TP, Smit AJ, Reitsma WD: Potassium channel modulation; effect of pinacidil on insulin release in healthy volunteers. J Clin Pharm 35: 291–294, 1995
Lingenberg JJ, Van-Haeften TW, Links TP, Smit AJ, Reitsma WD: Clinical relevance of ATP dependent potassium channels. Neth J Med 47: 241–251, 1995
Allman KC, Stevens MJ, Wieland DM, Hutchins GD, Wolfe ER Jr, Greene DA, Schwaiger M: Non invasive assessment of cardiac diabetic neuropathy by carbon 11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 22: 1425–1432, 1993
Erbas T, Erbas B, Gedik O, Biberoglu S, Bekdik CF: Scintigraphic evaluation of left ventricular function and correlation with autonomic cardiac neuropathy in diabetic patients. J Cardiology 81: 14–24, 1992
Khan JK, Sisson JC, Vinik AL: QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy. J Clin Endocr Metabol 64: 751–764, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mahgoub, M.A., Abd-Elfattah, A.S. Diabetes mellitus and cardiac function. Mol Cell Biochem 180, 59–64 (1998). https://doi.org/10.1023/A:1006834922035
Issue Date:
DOI: https://doi.org/10.1023/A:1006834922035